This detailed, expanded analysis explores key access and reimbursement topics in the rare disease space in the United States, such as the approaches managed care organizations take to control both utilization and costs of orphan drugs. The study further explores U.S. payers’ perspectives on market access considerations for several rare diseases including cystic fibrosis, Duchenne muscular dystrophy, hemophilia A, and idiopathic pulmonary fibrosis.

Related Reports

Rare Diseases and Orphan Drugs | Landscape & Forecast | Disease Landscape & Forecast: Gene Therapies for Rare Diseases

MARKET OUTLOOK Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide...

View Details

Rare Diseases and Orphan Drugs | Access & Reimbursement | Detailed, Expanded Analysis Orphan Drugs (EU)

MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of trea...

View Details